The largest database of trusted experimental protocols
> Disorders > Neoplastic Process > Prostate Cancer

Prostate Cancer

Prostate Cancer: A common type of cancer that originates in the prostate gland, a small walnut-shaped organ located below the bladder in men.
Prostate cancer typically grows slowly and remains confined to the prostate gland, but some types are more aggresive and can spread to other parts of the body.
Risk factors include older age, family history, and certain genetic mutations.
Symptoms may include difficulty urinating, blood in urine or semen, and bone pain.
Early detection through screening tests like PSA blood tests and prostate biopsies is key for effective treatment, which may include surgery, radiation therapy, hormonal therapy, or a combination of these approaches.
Ongoing research aims to improve diagnosis, prognosis, and personalized management of this prevalent male malignancy.

Most cited protocols related to «Prostate Cancer»

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2015
Blindness Cells DNA Chips Ethics Committees, Research Exome Freezing Malignant Neoplasms Methylation MicroRNAs Microtubule-Associated Proteins Neoplasm Metastasis Neoplasms Pathologists Patients Prostate Prostate Cancer Prostatic Intraepithelial Neoplasias Protein Arrays Proteins RNA Degradation Seminal Vesicles System, Genitourinary Tissues

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2010
Prostate Prostate Cancer
Flash-frozen needle biopsies and matched normal samples underwent nucleic acid extraction as previously described (5 (link)). Extracted DNA underwent whole-exome library construction and somatic mutation analysis as previously described. BAM files were aligned to the hg19 human genome build. Copy-number aberrations were quantified and reported for each gene as previously described (38 (link), 39 (link)). Amplifications and homozygous deletions for a set of 20 genes previously implicated in prostate cancer (SI Appendix, Table S3) underwent further confirmatory review of segmentation files. Annotation of known or likely oncogenic SNVs was performed using the OncoKB platform (16 (link)).
Transcriptome libraries were prepared as previously described (5 (link)), using polyA+ RNA isolation, or captured using Agilent SureSelect Human All Exon V4 reagents, or in some cases using both polyA and capture methods. Library quality assessment and sequencing were performed as previously described. Paired-end transcriptome-sequencing reads were aligned to the human reference genome (GRCh38) using STAR (40 (link)). Gene expression as fragments per kilobase of exon per million fragments mapped (FPKMs) was determined using featureCounts against protein-coding genes from the Gencode v26 reference. Fusions in ETS genes (ERG, ETV1, ETV4, ETV5, FLI1) and RAF1/BRAF were detected using CODAC (41 (link)) and assessed manually in all cases where RNA-sequencing data were available. In addition, the presence of AR splice variants was quantified as the number of reads across specific splice junctions in splice reads per million (SRPMs) and as the ratio of reads across a specific splice junction to the sum of AR promoter 1 and promoter 2 reads (a surrogate of total AR expression), separately for polyA and capture libraries.
NEPC and AR signaling scores were computed by the Pearson’s correlation coefficient between the log2-transformed FPKM values of each score’s gene list and a reference gene expression vector, as previously described (7 (link), 32 (link)). CCP and RB loss scores were computed by the average (i.e., mean) Z score-transformed expression levels across each score’s gene list, as previously described (42 (link), 43 (link)). A high correlation (R ≥ 0.95, P < 0.001, Pearson’s correlation test) was noted between scores derived from polyA versus capture RNA-sequencing libraries (SI Appendix, Fig. S8), allowing for joint analysis of samples sequenced with either library construction method.
All data from SNV, copy-number, and expression analysis as well as clinical characteristics and outcomes measures (Dataset S1) have been made available in cBioPortal (44 (link)) (www.cbioportal.org), and have been deposited in GitHub, https://github.com/cBioPortal/datahub/tree/master/public/prad_su2c_2019.
Publication 2019
BRAF protein, human Diploid Cell DNA Library Exome Exons Freezing Gene Deletion Gene Expression Gene Fusion Gene Products, Protein Genes Genetic Vectors Genome, Human Homo sapiens Homozygote isolation Joints Mutation Needle Biopsies Nucleic Acids Oncogenes Poly A Prostate Cancer Raf1 protein, human RNA, Polyadenylated Transcriptome Trees

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2010
Brachytherapy Patient Representatives Prostate Cancer Prostatectomy Radiotherapy
The Integrated Neuroendocrine Prostate Cancer (NEPC) score estimates the likelihood of a test sample to be CRPC-NE. It is calculated as the Pearson's correlation coefficient between the test vector and a reference CRPC-NE vector based on a set of 70 genes (Supplementary Table 9, Supplementary Fig. 10 and 15) using normalized FPKM values of the test sample. The gene set stems from the integration of differentially deleted/amplified and/or expressed and/or methylated genes in CRPC-NE and CRPC-Adeno. Specifically, 16 differentially deleted genes were selected among putative cancer genes31 (link) (see Differential copy number analysis). The following strategy was used to identify both differentially expressed genes that better distinguish CRPC-NE and CRPC-Adeno samples. We selected differentially expressed protein coding genes with FDR ≤ 1e-2, resulting in a total of 2425 genes, corresponding to 1301 over- and 1124 under-expressed. For each gene, we performed a Receiver Operator Curve (ROC) analysis using the normalized FPKMs as threshold parameter and calculated the Area Under the Curve (AUC). ROCs were built by considering only samples sequenced excluding two samples (7520 and 4240) that were previously published9 (link).leaving 34 CRPC-Adeno and 13 CRPC-NE. Only those differentially expressed genes with AUC ≥ 0.95 and with a fold-change greater than 2 or lower than 0.5 were included in the classifier, resulting in a list of 49 genes (25 over- and 24 under- expressed in CRPC-NE vs. CRPC-Adeno), 21 of which found as differentially methylated between CRPC-NE and CRPC-Adeno. Concordant information between RNA and Methylation was found for 11 genes (see Supplementary Table 9). In addition, we considered 2 genes (MYCN and AURKA) that we previously described as associated with CRPC-NE phenotype9 (link), EZH2 (FDR = 7.9*10−4) and DNMT1 (FDR = 6.9*10−5) for their role in controlling DNA methylation70 (link) and RB1 (FDR = 0.056), reported as a key driver in the pathogenesis of CRPC-NE9 (link),45 (link). For each of the resulting 70 genes, we calculated the mean of the normalized FPKM across the 13 CRPC-NE samples with RNA-seq data and defined the resulting set of averages as reference CRPC-NE vector. The Integrated NEPC score was tested across 719 prostate samples with available transcriptome data from multiple datasets (Supplementary Table 10). RNA-seq data were processed as described above. Processed SU2C-PCF26 (link) and Grasso et al21 (link) (Michigan 2012) data were downloaded from cBioPortal71 (link). Since data for 4 genes (ARHGAP8, BRINP1, C7Orf76 and MAP10) were not available from cBioPortal, for Michigan 2012 we used a reduced version of Integrated NEPC Score (indicated as Integrated NEPC Score*). Samples with Integrated NEPC Score greater than or equal to 0.40 (elevated Integrated NEPC score in main text) were nominated as putative CRPC-NE (Figure 4c, Supplementary Table 14). In order to take into account the lower signal-to-noise ratio and the reduced version of Integrated NEPC Score in Michigan 2012 microarray data, in Figure 4d we consider as CRPC-NE – like those samples with Integrated NEPC Score ≥ 0.25 (significant Integrated NEPC score in Figure 4 legend). AR signaling and Integrated NEPC Score values per sample are reported in Supplementary Table 15.
Publication 2016
Aurora Kinase A Cloning Vectors DNMT1 protein, human EZH2 protein, human Gene Products, Protein Genes Malignant Neoplasms Methylation Microarray Analysis MYCN protein, human Neurosecretory Systems pathogenesis Prostate Prostate Cancer RNA-Seq Stem, Plant Transcriptome

Most recents protocols related to «Prostate Cancer»

Not available on PMC !

Example 3

At the time of diagnosis with prostate cancer, subjects are invited to participate in a trial. A subject sample, e.g., blood, is obtained. Periodically, throughout the monitoring, watchful waiting, or active treatment of the subject, e.g., chemotherapy, radiation therapy, e.g., radiation of the prostate, surgery, e.g., surgical prostate resection, hormone therapy, a new subject sample is obtained. At the end of the study, all subject samples are tested for the level of FLNA and/or PSA, and optionally other markers. The subject samples are matched to the medical records of the subjects to correlate FLNA and/or PSA levels, as appropriate, with prostate cancer status at the time of diagnosis, rate of progression of disease, response of subjects to one or more interventions, and transitions between androgen dependent and independent status. Other markers, such as the expression level of keratin 19 and/or filamin B, the age of the subjects, or the prostate volume of the subjects, can also be analyzed in addition to filamin A and/or PSA.

Patent 2024
Androgens BLOOD Diagnosis Disease Progression Filamin A Filamin B Hormones Keratin-19 Operative Surgical Procedures Pharmacotherapy Prostate Prostate Cancer Prostatectomy Radiotherapy Therapeutics

Example 2

Using the antibodies of the invention as described herein, FLNA levels can be used to distinguish subjects who are or are not suffering from prostate cancer.

A series of subject samples are obtained from an appropriate source, e.g., a commercial source, wherein the samples were obtained from subjects with different stages of prostate cancer, e.g., aggressive prostate cancer, androgen sensitive, androgen insensitive, metastatic; or from subjects not suffering from prostate cancer, e.g., subjects with normal prostate or subjects with BPH. The samples are analyzed for the expression level of FLNA and/or PSA. Optionally other markers, such as the expression level of keratin 19 and/or filamin B, the age of the subjects, or the prostate volume of the subjects, can also be analyzed in addition to filamin A and/or PSA. The level of FLNA and PSA correlate with the presence or absence of disease, and with the severity of prostate cancer.

Patent 2024
Androgens Antibodies Filamin A Filamin B Keratin-19 Prostate Prostate Cancer
Not available on PMC !

Example 8

Serum samples from patients were tested with the FLNA IPMRM, as described above, using the anti-FLNA monoclonal antibodies of the invention. The results were combined with data on age, PSA, and Gleason score and subjected to regression modelling. As shown in FIG. 10, a Prostate Cancer Biomarker Panel consisting of biomarkers FLNA, FLNB, age and PSA improved the classification of prediction of prostate cancer over PSA alone (AUC=0.64, [0.59, 0.69], vs 0.58).

Samples of patient serum were also analyzed for the biomarkers FLNA, keratin 19 (KRT19) and age combined, versus PSA alone. FIG. 11 shows that the biomarkers FLNA, KRT19 and age have improved classification of prediction between patients with benign prostatic hyperplasia versus prostate cancer over PSA alone (AUC=0.70 [0.60, 0.80], vs 0.58).

Patent 2024
Anti-Antibodies Benign Prostatic Hyperplasia Biological Markers Keratin-19 Monoclonal Antibodies Patients Prostate Prostate Cancer Serum Tumor Markers
Ovarian cancer cell lines A2780 and SKOV-3 were obtained from the institutional Cell Line Core Laboratory of the MD Anderson Cancer Center. Prostate cancer cell lines LNCaP and PC-3 were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA), as well as the NIH3T3 normal cell line. Ovarian cell lines were grown in RPMI-1640 (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 15% fetal bovine serum (FBS; Life Technologies, Carlsbad, CA, USA), 2.0 g sodium bicarbonate, 0.1% gentamicin solution. LNCaP cells were cultured in RPMI-1640 supplemented with 10% FBS, 1.5 g sodium bicarbonate, 2.5 g glucose, 2.383 g HEPES, 0.11 g sodium pyruvate and 1% penicillin/streptomycin. The PC-3 cell line was grown in DMEM (high glucose) complemented with 10% FBS, 1.5 g sodium bicarbonate, 0.22 g sodium pyruvate and 1% penicillin/streptomycin. NIH3T3 cell line was cultured in DMEM (high glucose) supplemented with 10% FBS, 2.7 g sodium bicarbonate and 1% penicillin/streptomycin. All cell lines were incubated at 37 °C in 5% CO2. All the other reagents were purchased from Sigma-Aldrich. The cell lines were certified free of mycoplasma (read B/read A ratio below 0.9; see figure S7 in Supplementary Information) using the MycoAlert® mycoplasma detection kit and MycoAlert® assay control set (Lonza, Morristown, NJ, USA). Subsection C in Supplementary Information provides details regarding the management and cell counting of these cell lines.
Publication 2023
Bicarbonate, Sodium Biological Assay Cell Lines Cells Gentamicin Glucose HEPES Malignant Neoplasms Mycoplasma NIH 3T3 Cells Ovarian Cancer Ovary PC 3 Cell Line Penicillins Prostate Cancer Pyruvate Sodium Streptomycin
With the idea of an MFH technique limited only to small tumor sizes, a special instrument was needed to deliver the heat in a minimally invasive manner. One potential end use of the LIH is during a laparoscopic procedure, a minimal invasive surgery where the surgeon inserts multiple tube-like instruments (with different functions) through small incisions in the patient’s body [53 –56 (link)]. This instrument was designed with a tube-like structure, considering current laparoscopic instrument designs, and its performance is mainly limited by the magnetic generator parameters and the electrical current flowing through it. The TRIH was designed for prostate cancer malignancies. This instrument could be used to reach the prostate transrectally or to access the prostate by placing it in contact with the perineum. A normal prostate has a volume of approximately 25 cm3. Nevertheless, in cases of benign prostate hyperplasia (BPH) or prostate cancer, the prostate volume can increase to over 30 cm3. This was the rationale behind designing this coil larger than the one in the LIH.
The enclosures for each instrument were designed to have a medical device appearance, while also providing a means to maintain the internal temperature of the coil below 155 °C to avoid damage. Both embodiments were designed using NX software (Siemens, Plano, TX, USA) and were partially constructed by a Zortrax Inkspire 3D printer (Zortrax SA, Olsztyn, Poland) with epoxy-based resin from the same company. The constructs can regulate the coil temperature by circulating water (20 °C–25 °C) throughout the instrument similar as inside MFH coils [57 (link)]. The materials for the LIH design and its measurements were selected considering the dimensions of current laparoscopic instruments. A polycarbonate tubing (⌀inner = 12.7 mm × ⌀outer = 15.9 mm × 1.6 mm wall) (Small Parts Inc., Logansport, IN, USA) connected the 3D printed parts (handle and tip). The handle included the water inlet and outlets, as well as a nylon wet-location multi-cord grip (McMaster-Carr, Elmhurst, IL, USA) for the 6 AWG Type 2 Litz wires that connect directly to the circuit. The tip was where the coil was placed and served as a connection point for the Masterflex® 25 L/S® inner tubing (Cole-Palmer, Vernon Hills, IL, USA). This ensures that the water flows right into the coil before exiting the instrument. A cap at the tip ensured fast replacement of the coil if a problem was encountered. The overall length of the LIH was approximately 23 cm (see figure 3(a)).
The TRIH design was similar in the parts used, but different in shape. In this case, a tygon flexible tubing (⌀inner = 25.4 mm × ⌀outer = 31.8 mm × 3.2 mm wall) (McMaster-Carr, Elmhurst, IL, USA) connected the 3D printed parts (handle and tip). Similar to the LIH, the handle included the water inlet and outlets, as well as the nylon wet-location multi-cord grip for the 6 AWG Type 2 Litz wires that connect directly to the circuit. The tip in this case also enclosed the coil and served as a connection point for the 25 L/S® inner tubing. This part had a 4-jet nozzle for improved heat removal of this larger coil. This design also had a cap for fast replacement of the coil if a problem was encountered. Because of the 3D printed enclosure, the instrument itself is slightly larger than what we aim to use in the future. However, this does not affect its performance, as the coil has the exact dimensions we designed for. The overall length of the TRIH was approximately 25 cm (see figure 3(b)).
Publication 2023
Benign Prostatic Hyperplasia Cone-Rod Dystrophy 2 Electricity Epoxy Resins Grasp Human Body Laparoscopy Malignant Neoplasms Medical Devices Minimally Invasive Surgical Procedures Neoplasms nylon 6 Nylons Patients Perineum polycarbonate Prostate Prostate Cancer Surgeons

Top products related to «Prostate Cancer»

Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
Sourced in United States, United Kingdom, Italy, Germany, France, China, Canada, Denmark, Switzerland, Spain, Australia
The LNCaP cell line is a human prostate adenocarcinoma cell line. It is a well-characterized in vitro model system for the study of prostate cancer.
Sourced in United States, United Kingdom, China, France, Germany, Sweden, Canada, Australia, Japan
The DU145 is a laboratory cell line derived from a human prostate carcinoma. It is widely used in cancer research for the study of cell biology and the development of potential therapies.
Sourced in United States, China, Germany, United Kingdom, Japan, France, Canada, Australia, Italy, Switzerland, Belgium, New Zealand, Spain, Israel, Sweden, Denmark, Macao, Brazil, Ireland, India, Austria, Netherlands, Holy See (Vatican City State), Poland, Norway, Cameroon, Hong Kong, Morocco, Singapore, Thailand, Argentina, Taiwan, Province of China, Palestine, State of, Finland, Colombia, United Arab Emirates
RPMI 1640 medium is a commonly used cell culture medium developed at Roswell Park Memorial Institute. It is a balanced salt solution that provides essential nutrients, vitamins, and amino acids to support the growth and maintenance of a variety of cell types in vitro.
Sourced in United States, Germany, United Kingdom, China, Canada, France, Japan, Australia, Switzerland, Israel, Italy, Belgium, Austria, Spain, Gabon, Ireland, New Zealand, Sweden, Netherlands, Denmark, Brazil, Macao, India, Singapore, Poland, Argentina, Cameroon, Uruguay, Morocco, Panama, Colombia, Holy See (Vatican City State), Hungary, Norway, Portugal, Mexico, Thailand, Palestine, State of, Finland, Moldova, Republic of, Jamaica, Czechia
Penicillin/streptomycin is a commonly used antibiotic solution for cell culture applications. It contains a combination of penicillin and streptomycin, which are broad-spectrum antibiotics that inhibit the growth of both Gram-positive and Gram-negative bacteria.
Sourced in United States, China, United Kingdom, Germany, France, Canada, Japan, Australia, Italy, Switzerland, Belgium, New Zealand, Austria, Netherlands, Israel, Sweden, Denmark, India, Ireland, Spain, Brazil, Norway, Argentina, Macao, Poland, Holy See (Vatican City State), Mexico, Hong Kong, Portugal, Cameroon
RPMI 1640 is a common cell culture medium used for the in vitro cultivation of a variety of cells, including human and animal cells. It provides a balanced salt solution and a source of essential nutrients and growth factors to support cell growth and proliferation.
Sourced in United States, China, United Kingdom, Germany, France, Australia, Canada, Japan, Italy, Switzerland, Belgium, Austria, Spain, Israel, New Zealand, Ireland, Denmark, India, Poland, Sweden, Argentina, Netherlands, Brazil, Macao, Singapore, Sao Tome and Principe, Cameroon, Hong Kong, Portugal, Morocco, Hungary, Finland, Puerto Rico, Holy See (Vatican City State), Gabon, Bulgaria, Norway, Jamaica
DMEM (Dulbecco's Modified Eagle's Medium) is a cell culture medium formulated to support the growth and maintenance of a variety of cell types, including mammalian cells. It provides essential nutrients, amino acids, vitamins, and other components necessary for cell proliferation and survival in an in vitro environment.
Sourced in United States, United Kingdom, Germany, China, France, Canada, Japan, Australia, Switzerland, Italy, Israel, Belgium, Austria, Spain, Brazil, Netherlands, Gabon, Denmark, Poland, Ireland, New Zealand, Sweden, Argentina, India, Macao, Uruguay, Portugal, Holy See (Vatican City State), Czechia, Singapore, Panama, Thailand, Moldova, Republic of, Finland, Morocco
Penicillin is a type of antibiotic used in laboratory settings. It is a broad-spectrum antimicrobial agent effective against a variety of bacteria. Penicillin functions by disrupting the bacterial cell wall, leading to cell death.
Sourced in United States, United Kingdom, Germany, China, France, Canada, Australia, Japan, Switzerland, Italy, Belgium, Israel, Austria, Spain, Netherlands, Poland, Brazil, Denmark, Argentina, Sweden, New Zealand, Ireland, India, Gabon, Macao, Portugal, Czechia, Singapore, Norway, Thailand, Uruguay, Moldova, Republic of, Finland, Panama
Streptomycin is a broad-spectrum antibiotic used in laboratory settings. It functions as a protein synthesis inhibitor, targeting the 30S subunit of bacterial ribosomes, which plays a crucial role in the translation of genetic information into proteins. Streptomycin is commonly used in microbiological research and applications that require selective inhibition of bacterial growth.
Sourced in United States, Germany, United Kingdom, Japan, Italy, China, Macao, Switzerland, France, Canada, Sao Tome and Principe, Spain, Australia, Ireland, Poland, Belgium, Denmark, India, Sweden, Israel, Austria, Brazil, Czechia, Netherlands, Portugal, Norway, Holy See (Vatican City State), New Zealand, Hungary, Senegal, Argentina, Thailand, Singapore, Ukraine, Mexico
FBS, or Fetal Bovine Serum, is a commonly used cell culture supplement. It is derived from the blood of bovine fetuses and provides essential growth factors, hormones, and other nutrients to support the growth and proliferation of a wide range of cell types in vitro.

More about "Prostate Cancer"

Prostate cancer is a common malignancy that originates in the prostate gland, a small, walnut-shaped organ located beneath the bladder in men.
This type of cancer typically grows slowly and remains confined to the prostate, but some more aggressive varieties can spread to other parts of the body.
Risk factors for prostate cancer include older age, family history, and certain genetic mutations.
Symptoms of prostate cancer may include difficulty urinating, blood in the urine or semen, and bone pain.
Early detection through screening tests like PSA (prostate-specific antigen) blood tests and prostate biopsies is crucial for effective treatment, which can involve surgery, radiation therapy, hormonal therapy, or a combination of these approaches.
Ongoing research aims to improve the diagnosis, prognosis, and personalized management of this prevalent male malignancy.
Cell lines like FBS, LNCaP, and DU145, as well as culture media like RPMI 1640 and DMEM supplemented with penicillin and streptomycin, are commonly used in prostate cancer research to study the biology and behavior of this disease.
By utilizing the insights gained from these tools and resources, researchers can work towards enhancing the understanding and treatment of prostate cancer, ultimately improving outcomes for those affected by this condition.